(บทความวิจัย) การวิเคราะห์ทรานสคริปโตมิกส์แบบบูรณาการแสดงให้เห็นตัวบ่งชี้ทางชีวภาพ และเป้าหมายการรักษาที่มีศักยภาพสำหรับการติดเชื้อร่วมวัณโรคและเอชไอวี

Thitiilat Chiraunyanann

Authors

Thitiilat Chiraunyanann Department of Disease Control, Ministry of Public Health, Nonthaburi Province, Thailand

Keywords:

Gene Set Enrichment Analysis, Host-directed therapy, IDO1, Transcriptomic biomarkers, Tuberculosis, HIV co-infection

Abstract

Tuberculosis and HIV co-infection constitute an important global health burden, with approximately 187,000 tuberculosis-related deaths annually among people living with HIV. Despite clinical urgency, current biomarkers demonstrate limited sensitivity and specificity for detecting active tuberculosis among HIV-positive individuals. This study, therefore, conducted an integrated analysis of transcriptomic data from four independent datasets encompassing 670 samples: 185 TB-HIV co-infected patients, 162 HIV mono-infected individuals, 179 tuberculosis-only patients, and 144 healthy controls from South Africa, Uganda, the United Kingdom, and India. Following rigorous quality control and batch effect correction using ComBat (sva package v3.46.0, R v4.3.0), differential expression analysis (limma) and Gene Set Enrichment Analysis (GSEA) were performed according to Broad Institute standard protocols. The analysis identified 34 robust biomarkers with an area under the receiver operating characteristic (ROC) curve of 0.947 (95% CI: 0.923-0.971), sensitivity of 88.9%, and specificity of 93.6%. GSEA revealed 47 significantly enriched biological pathways (FDR < 0.001), including interferon-gamma response (NES = 2.89), tryptophan catabolism (NES = 2.67), and IDO1 as a central metabolic checkpoint. Network topology analysis identified 12 high-confidence therapeutic targets, including CXCL10 and IDO1. Cross-validation across independent cohorts confirmed classification accuracy of 91.2%.

References

World Health Organization. Global tuberculosis report 2023. Geneva: WHO; 2023. Available from: https://www.who.int/publications/i/item/9789240083851.

Pawlowski A, Jansson M, Sköld M, Rottenberg ME, Källenius G. Tuberculosis and HIV coinfection. PLoS Pathog 2012; 8: e1002464. doi:10.1371/journal.ppat.1002464.

Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 2010; 50: S201207. doi:10.1086/651492.

Lawn SD, Zumla AI. Tuberculosis. Lancet 2011; 378: 5772. doi:10.1016/S01406736(10)621733.

Bell LCK, Noursadeghi M. Pathogenesis of HIV1 and Mycobacterium tuberculosis coinfection. Nat Rev Microbiol 2018; 16: 8093. doi:10.1038/nrmicro.2017.128.

Hasin Y, Seldin M, Lusis A. Multiomics approaches to disease. Genome Biol 2017; 18: 83. doi:10.1186/s1305901712151.

Olivier M, Asmis R, Hawkins GA, Howard TD, Cox LA. The need for multiomics biomarker signatures in precision medicine. Nat Rev Clin Oncol 2019; 16: 741754. doi:10.1038/s4157101902486.

Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973977. doi:10.1038/nature09247.

Sweeney TE, Braviak L, Tato CM, Khatri P. Genomewide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis. Lancet Respir Med 2016; 4: 213224. doi:10.1016/S22132600

(16)000485.

PennNicholson A, Mbandi SK, Thompson E, et al. RISK6, a 6gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Sci Rep 2020; 10: 8629. doi:10.1038/s41598020650438.

Scriba TJ, PennNicholson A, Shankar S, et al. Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. PLoS Pathog 2017; 13: e1006687.

MacLean E, Broger T, Yerliyaka S, et al. A systematic review of biomarkers to detect active tuberculosis. Nat Microbiol 2019; 4: 748758. doi:10.1038/s4156401903802.

Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 2003; 188: 11461155. doi:10.1086/378676.

Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 1554515550. doi:10.1073/pnas. 0506580102.

Liberzon A, Birger C, Thorvaldsdóttir H, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst 2015; 1: 417425. doi:10.1016/j.cels.2015.12.004.

Mootha VK, Lindgren CM, Eriksson KF, et al. PGC1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267273.

Gautam US, Foreman TW, Bucsan AN, et al. In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immunemediated control of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2018; 115: E62E71. doi:10.1073/pnas.1711373114.

Muller AJ, Sharma MD, Chandler PR, et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A 2008; 105: 1707317078.

Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostat 2007; 8: 118127. doi:10.1093/biostatistics/kxj037.

Leek JT, Johnson WE, Parker HS, et al. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 2012; 28: 882883.

Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA sequencing and microarray studies. Nucleic Acids Res 2015; 43: e47. doi:10.1093/nar/gkv007.

Weiner J 3rd, Parida SK, Maertzdorf J, et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One 2012; 7: e40221.

Kumar NP, Moideen K, Sivakumar S, et al. Plasma proinflammatory cytokines are markers of disease severity and bacterial burden in pulmonary tuberculosis. Open Forum Infect Dis 2019; 6: ofz257.

Wallis RS, Ginindza S, Beattie T, et al. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med 2021; 9: 897908.

Cazabon D, Alsdurf H, Satyanarayana S, et al. Quality of tuberculosis care in high-burden countries: the urgent need to address gaps in the care cascade. Int J Infect Dis 2017; 56: 111116.

Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers 2016; 2: 16076. doi:10.1038/nrdp. 2016.76.

Bisson GP, Mehaffy C, Broeckling C, et al. Upregulation of alpha1-antitrypsin in chronic HIV infection correlates with markers of immune activation and inflammation. PLoS One 2014; 9: e95664.